Business Context and Reporting Period
This Form 8-K is filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on November 8, 2018. The report serves to furnish the Company's press release detailing financial results for the third quarter ended September 30, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text is a cover sheet for the filing and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, no specific financial values are available in this text.
Material Changes
The filing text does not provide specific comparative data or describe material changes versus the prior period. It only indicates that results for the third quarter of 2018 were reported.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information is furnished pursuant to Item 2.02 and is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name is Gemphire Therapeutics Inc., as the input metadata incorrectly listed "Metavia Inc."
- Review Exhibit 99.1 (the Press Release dated November 8, 2018) to obtain actual revenue, net loss, and cash position figures.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 liability standards.